Navigation Links
Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice

ALBUQUERQUE, N.M., Feb. 16 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

Under the agreement, EndoChoice's experienced, gastroenterology-focused sales force will introduce Exagen's proprietary gene expression tests for the diagnosis of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).  Exagen developed these molecular tests through its discovery engine, Coperna®, which identified "gene activity signatures" associated with IBD and IBS.

Scott Glenn, Exagen's CEO said, "We are excited about the opportunity of partnering with EndoChoice to accelerate the adoption of our technology by gastroenterologists.  Our eXaIBD™ and eXaIBS™ tests have both high sensitivity and accuracy, helping to identify IBD and IBS from other diseases, avoiding an extensive series of exclusionary testing."

"EndoChoice is focused on satisfying the unmet needs of GI professionals by delivering innovative, best-in-class products and services," said Mark Gilreath, EndoChoice's CEO.  "We are pleased to offer Exagen's proprietary eXaIBD™ and eXaIBS™ tests because they provide a superior diagnostic tool to assist gastroenterologists and improve patient care."

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit

About EndoChoice, Inc.

EndoChoice delivers innovative solutions to professionals in gastrointestinal endoscopy with its diverse portfolio of high-quality diagnostics, equipment, devices, supplies and services.   The company strives to cleverly exceed its customers' expectations through its nationwide sales force, exemplary customer care, superior products and easy online ordering.  For more information, visit

SOURCE Exagen Diagnostics, Inc.



SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
2. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
3. Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
4. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
5. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
6. Fujirebio Diagnostics Named Life Sciences Company of the Year
7. U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
8. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
9. Roche Diagnostics Opens State-of-the-Art Training Center in California
10. Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
11. Reportlinker Adds Molecular Diagnostics - A World Market Review
Post Your Comments:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):